The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Xerava
eravacycline · ERAVACYCLINE DIHYDROCHLORIDE 50 mg/1 · Injection, Powder, Lyophilized, For Solution · Intravenous · Tetraphase Pharmaceuticals, Inc.
NDC 71773-0050-05 · 1 VIAL, GLASS in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$57.00
Reported to Texas DSHS · 2024 annual filing · Tetraphase Pharmaceuticals, Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2024)
$20,164
35 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- analysis
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $817.77 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA211109
- TE code
- —
- Approval date
- Aug 27, 2018
- Patents / exclusivity
- 8 patents, 4 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | GAIN | Aug 27, 2028 |
| exclusivity | GAIN | Aug 27, 2028 |
| exclusivity | NCE | Aug 27, 2023 |
| exclusivity | NCE | Aug 27, 2023 |
| patent | 11578044 | Oct 19, 2037 |
| patent | 11578044 | Oct 19, 2037 |
| patent | 10961190 | Oct 19, 2037 |
| patent | 10961190 | Oct 19, 2037 |
| patent | 8906887 | Aug 27, 2032 |
| patent | 8906887 | Aug 27, 2032 |
| patent | 8796245 | Aug 7, 2029 |
| patent | 8796245 | Aug 7, 2029 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of eravacycline (Injection, Powder, Lyophilized, For Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Tetraphase Pharmaceuticals, Inc. | ERAVACYCLINE DIHYDROCHLORIDE 100 mg/1 | Jul 15, 2026 | Sep 1, 2026 |
| Tetraphase Pharmaceuticals, Inc. | ERAVACYCLINE DIHYDROCHLORIDE 50 mg/1 | Jul 15, 2026 | Sep 1, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Xerava — NDC 71773-0050-05," retrieved September 3, 2026, https://drugdashboards.com/drug/71773005005.
Free to cite with attribution — see how the data is put together.